Researcher.Life Logo

PharmacoEconomics - Open : Impact Factor & More

eISSN: 2509-4254pISSN: 2509-4262
JournalOpen Access

Key Metrics

CiteScore
2.9
H-Index
17
SJR
Q2Pharmacology
SNIP
0.78
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on PharmacoEconomics - Open

PharmacoEconomics - Open Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGER INT PUBL AG
Language English
Frequency Quarterly
Article Processing ChargesEUR 2790 | USD 3490 | GBP 2390
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2017
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in PharmacoEconomics - Open ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in PharmacoEconomics - Open

Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies.
  • 19 May 2026
  • PharmacoEconomics - open
Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness Study.
  • 8 May 2026
  • PharmacoEconomics - open
Estimating Eligibility for Lung Cancer Screening in Ireland: A Dynamic Modelling Study of Smoking Trends.
  • 4 May 2026
  • PharmacoEconomics - open
Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop.
  • 3 May 2026
  • PharmacoEconomics - open
Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?
  • 21 Apr 2026
  • PharmacoEconomics - open
Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting.
  • 16 Apr 2026
  • PharmacoEconomics - open
Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies.
  • 19 May 2026
  • PharmacoEconomics - open
Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness Study.
  • 8 May 2026
  • PharmacoEconomics - open
Estimating Eligibility for Lung Cancer Screening in Ireland: A Dynamic Modelling Study of Smoking Trends.
  • 4 May 2026
  • PharmacoEconomics - open
Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop.
  • 3 May 2026
  • PharmacoEconomics - open
Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?
  • 21 Apr 2026
  • PharmacoEconomics - open
Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting.
  • 16 Apr 2026
  • PharmacoEconomics - open

FAQs on PharmacoEconomics - Open